Amgen

Open: 224.44 Close: 223.42 Change: -1.02

Stop waiting time to find out about Amgen: Our AI summarizes all info about it.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Federal Trade Commission said the deal would enable Amgen to exploit its size to block competition. FTC said it believed Amgen could leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers.

Today's News

U.S. sues to block amgens $27.8 billion takeover of horizon therapeutics - The New York Times. The Federal Trade Commission said the deal would enable Amgen to exploit its size to block competition. Federal Trade Commission is suing to block biotech drug developer Amgens more than $26 billion deal for Horizon Therapeutics. If completed, the deal would give Amgen access to Horizons blockbuster thyroid eye disease drug, Tepezza and its gout medicine Krystexxa. Federal Trade Commission (FTC) announced Tuesday that it will oppose the Amgen-Horizon deal on grounds it will stifle innovation and the development of new drugs. FTC said it believed Amgen could leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers. FTC Moves to Block Amgens $27.8 billion deal for horizon therapeutics - wsj. ftc moves to block amgens. $27.8 billion acquisition of Horizon. Federal Trade Commissions (FTC) lawsuit filed on Tuesday surprised those who had brushed off the antitrust risk in Amgens deal because of its limited business overlap with Horizon Therapeutics. FTC said it opposed the deal because it was concerned that Amgen could use rebates to pharmacy benefit managers in exchange for promoting key products. Federal Trade Commissions (FTC) complaint seeking to block the companys proposed acquisition of Horizon Therapeutics plc: Amgen agrees not to seek quick close to Horizon acquisition. Amgen announced plans to buy Horizon in December, saying its rare disease drugs would offer it some protection from the drug pricing provisions of the Inflation Reduction Act. U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents. FTC sues to block Amgens $27.8 billion purchase of Horizon Therapeutics. FTC is attempting to stop the sale out of fears it will give the company too much power. Federal Trade Commission said on Tuesday it has filed a lawsuit to stop Amgen Incs $27.8 billion acquisition of Horizon Therapeutics Plc in a rare move to block a large pharmaceutical deal. FTC is preparing to seek an injunction in federal court that would prevent the deal from closing. Amgen reported an EPS of $3.98 in its last earnings report, beating expectations of $2.847. Amgen Dún Laoghaire consists of a 37,000 square metre aseptic manufacturing facility in Dúlaghaire, Ireland. Federal Trade Commission filed a lawsuit Tuesday to block Amgens $27.8 billion purchase of Horizon Therapeutics. FTC said the deal would give Amgen unfair leverage to block competition for Horizon medications. FTC Sues to Block Amgens $27.8 Billion Acquisition of Horizon Therapeutics. FTC said Tuesday that the deal would give Amgen unfair leverage to block competition for Horizon medications. Shares of Amgen Inc., based in Thousand Oaks, California, slipped 1% Tuesday afternoon to $231.14 while broader indexes were mixed. The Federal Trade Commission (FTC) on Tuesday filed a lawsuit to block Amgen s $27.8 billion   acquisition   of Horizon Therapeutics. Federal Trade Commission is seeking to block biopharmaceutical giant Amgen from acquiring Horizon Therapeutics plc. The $27.8 billion acquisition would enable Amgen Inc. to stifle competition for thyroid eye disease and chronic refractory gout treatments, the agency says. Federal Trade Commission filed a lawsuit Tuesday seeking an injunction to prevent Amgens buyout of Horizon Therapeutics, which the agency says would “entrench monopoly drugs” The Federal Trade Commission (FTC) announced on May 16, 2023 that the agency is filing suit against Amgen in conjunction with Amgens recent $27.8 billion bid to acquire Horizon Therapeutics. In response to the suit, Amgen released a public statement denying its intentions to bundle coverage.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, FTC, block, Federal, Trade, deal, and the most common words in the summary are: amgen, stock, horizon, ftc, news, deal, amgens, . One of the sentences in the summary was: FTC said it believed Amgen could leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #horizon #ftc #news #deal #amgens.